What is the value of maintenance therapy in advanced NSCLC, and who should...
_kmq.push(["trackClickOnOutboundLink","wpa2a_84","Article link clicked",{"Title":"","Page":"What is the value of maintenance therapy in advanced NSCLC, and who should get it?"}]);We’ve covered the...
View ArticleCore Principles of Managing Locally Advanced (Stage III) NSCLC
_kmq.push(["trackClickOnOutboundLink","wpa2a_80","Article link clicked",{"Title":"","Page":"Core Principles of Managing Locally Advanced (Stage III) NSCLC"}]);Here’s a text-heavy but still brief...
View ArticleNew Approval for Zykadia (LDK378/ceritinib) in ALK-Positive NSCLC: Why It...
_kmq.push(["trackClickOnOutboundLink","wpa2a_76","Article link clicked",{"Title":"","Page":"New Approval for Zykadia (LDK378\/ceritinib) in ALK-Positive NSCLC: Why It Matters Even if You’re Not...
View ArticleTransitioning Survival from Months to Years in Advanced NSCLC
_kmq.push(["trackClickOnOutboundLink","wpa2a_72","Article link clicked",{"Title":"","Page":"Transitioning Survival from Months to Years in Advanced NSCLC"}]);This is a slide presentation I did last...
View ArticleTop 10 Key Presentations at ASCO 2014: Join Us for Discussion at Upcoming...
_kmq.push(["trackClickOnOutboundLink","wpa2a_68","Article link clicked",{"Title":"","Page":"Top 10 Key Presentations at ASCO 2014: Join Us for Discussion at Upcoming #LCSM Chat...
View ArticleShould We Add Avastin (Bevacizumab) to Tarceva (Erlotinib) for EGFR...
_kmq.push(["trackClickOnOutboundLink","wpa2a_64","Article link clicked",{"Title":"","Page":"Should We Add Avastin (Bevacizumab) to Tarceva (Erlotinib) for EGFR Mutation-Positive NSCLC?"}]);I recently...
View ArticleGilotrif (Afatinib) Reports Survival Benefit for EGFR Mutation-Positive...
_kmq.push(["trackClickOnOutboundLink","wpa2a_60","Article link clicked",{"Title":"","Page":"Gilotrif (Afatinib) Reports Survival Benefit for EGFR Mutation-Positive Advanced NSCLC: Is it a Superior EGFR...
View ArticleNot all EGFR Activating Mutations are Created Equal: Time to Stop Pooling...
_kmq.push(["trackClickOnOutboundLink","wpa2a_56","Article link clicked",{"Title":"","Page":"Not all EGFR Activating Mutations are Created Equal: Time to Stop Pooling Them Together"}]);It’s been a...
View ArticleWhy T790M status matters: The new value proposition for repeat biopsies in...
_kmq.push(["trackClickOnOutboundLink","wpa2a_52","Article link clicked",{"Title":"","Page":"Why T790M status matters: The new value proposition for repeat biopsies in acquired resistance"}]);One of the...
View ArticleUpcoming Tweet Chat July 17th: Help us define the benefit of online resources...
_kmq.push(["trackClickOnOutboundLink","wpa2a_48","Article link clicked",{"Title":"","Page":"Upcoming Tweet Chat July 17th: Help us define the benefit of online resources for cancer...
View ArticleUniversity of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens...
_kmq.push(["trackClickOnOutboundLink","wpa2a_44","Article link clicked",{"Title":"","Page":"University of Colorado\u2019s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of...
View ArticleContinuing EGFR TKI Therapy Beyond Progression in EGFR Mutation-Positive Lung...
_kmq.push(["trackClickOnOutboundLink","wpa2a_40","Article link clicked",{"Title":"","Page":"Continuing EGFR TKI Therapy Beyond Progression in EGFR Mutation-Positive Lung Cancer: IMPRESS Provides New...
View ArticleCyramza, New Angiogenesis Inhibitor, Approved with Taxotere for Second Line...
_kmq.push(["trackClickOnOutboundLink","wpa2a_36","Article link clicked",{"Title":"","Page":"Cyramza, New Angiogenesis Inhibitor, Approved with Taxotere for Second Line NSCLC: Let’s Review Why"}]);It...
View ArticleMy Top Five Highlights in Lung Cancer from 2014
_kmq.push(["trackClickOnOutboundLink","wpa2a_32","Article link clicked",{"Title":"","Page":"My Top Five Highlights in Lung Cancer from 2014"}]);An annual tradition is a reflection on the key...
View ArticleHow Do Patients Decide Where to Seek Cancer Treatment?
_kmq.push(["trackClickOnOutboundLink","wpa2a_28","Article link clicked",{"Title":"","Page":"How Do Patients Decide Where to Seek Cancer Treatment?"}]);Cancer is both a terrible, terrifying disease and...
View ArticleImmunotherapy Opdivo (Nivolumab) Approved for Chemo-Pretreated Advanced...
_kmq.push(["trackClickOnOutboundLink","wpa2a_24","Article link clicked",{"Title":"","Page":"Immunotherapy Opdivo (Nivolumab) Approved for Chemo-Pretreated Advanced Squamous NSCLC"}]);It was a big day...
View ArticleImmunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported...
_kmq.push(["trackClickOnOutboundLink","wpa2a_20","Article link clicked",{"Title":"","Page":"Immunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported as Positive"}]);In January, 2015,...
View ArticleThe Immunotherapy Cola Wars
_kmq.push(["trackClickOnOutboundLink","wpa2a_16","Article link clicked",{"Title":"","Page":"The Immunotherapy Cola Wars"}]);It’s been a big week for immunotherapy for lung cancer. Right on the heels of...
View ArticlePFS vs. pfs: Why Progression-Free Survival Remains Controversial in Lung Cancer
_kmq.push(["trackClickOnOutboundLink","wpa2a_12","Article link clicked",{"Title":"","Page":"PFS vs. pfs: Why Progression-Free Survival Remains Controversial in Lung Cancer"}]);Last year, an article...
View ArticleRattling the SABR: Provocative but Limited Data Supporting a Non-Surgical...
_kmq.push(["trackClickOnOutboundLink","wpa2a_8","Article link clicked",{"Title":"","Page":"Rattling the SABR: Provocative but Limited Data Supporting a Non-Surgical Approach to Early Stage...
View Article
